CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis hasn't changed. Novo Nordisk is still a dominant player in a growing industry, ...

Touchstone and Rowley highlight why companies like Eli Lilly, Novo Nordisk, and Genentech are choosing to set up shop in ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...